Genetic Predisposition to Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine 24-5 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Genetic Predisposition to Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine 24-5 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

This issue serves as a timely review of both the genetic and genomic factors resulting in a predisposition to human cancer.  There is now strong evidence to support the use of genetic testing for cancer predisposition in the practice of preventive medicine, and at the same time, there is emerging new literature defining the role of genomic approaches to assessment of cancer predisposition.  Articles address predisposition syndromes in the areas of breast cancer, lower GI cancer, genitourinary cancer, pediatric cancer, endocrine cancer, and hematologic malignancy.

Read more and order at Genetic Predisposition to Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine 24-5

Pancreatic Cancer: Current Concepts in Treatment and Research, An Issue of Surgical Oncology Clinics. The Clinics: Surgery 19-2 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Pancreatic Cancer: Current Concepts in Treatment and Research, An Issue of Surgical Oncology Clinics. The Clinics: Surgery 19-2 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

This issue of the Surgical Oncology Clinics will cover the following topics: imaging for pancreatic cancer, EUS staging and novel therapeutics for pancreatic cancer, management of cystic tumors, management of IPMN, laparoscopic surgery for pancreatic tumors, current concepts in the surgical management of pancreatic cancer, management of borderline resectable pancreatic cancer, regionalization of pancreatic surgery, update on adjuvant trials for pancreatic cancer, neoadjuvant therapy for pancreatic cancer, novel targets for pancreatic cancer therapy, and new frontiers in pancreatic cancer.

Read more and order at Pancreatic Cancer: Current Concepts in Treatment and Research, An Issue of Surgical Oncology Clinics. The Clinics: Surgery 19-2

2016-2020 U.S. POC/Point-of-Care Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The 2016-2020 U.S. POC/Point-of-Care Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

This new 418-page report from contains 42 tables, and provides a comprehensive analysis of thePOC coagulation testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&ampD and marketing strategies for the global POC coagulation market.

Rationale

The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.

Market Segmentation Analysis

– Review of nine POC market segments, including their dynamics, trends, structure,
size, growth and major suppliers.

– Five-year test volume and reagent sales forecasts for coagulation procedures
by market segment:

– Physician Offices/Group Practices
– Emergency Rooms
– Operating/Recovery Suites
– ICUs/CCUs
– Cancer Clinics
– Ambulatory Care Centers
– Surgery Centers
– Nursing Homes
– Birth Centers

Sales and Market Share Analysis

– Sales and market shares of major coagulation reagent and instrument suppliers.

Current and Emerging Products

– Analysis of coagulation procedures performed in POC testing locations.
– Review of leading coagulation analyzers, both currently marketed and
those in development, including their operating characteristics, features and selling prices.

Technology Review

– Emerging technologies and their applications for POC testing.
– Comprehensive listings of companies developing or marketing coagulation
testing technologies and products, by assay.

Competitive Assessments

– Assessments of major suppliers and emerging market entrants,
including their sales, product portfolios, marketing tactics, joint ventures,
and new products in R&ampD.

Strategic Recommendations

– Specific opportunities for new coagulation instruments and reagent systems with potentially
significant market appeal during the next five years.
– Design criteria for POC testing products.
– Alternative business expansion strategies.
– Potential market entry barriers and risks.

Methodology

This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and &#039s proprietary data files.

Contains 418 pages and42 tables

Read more and order at 2016-2020 U.S. POC/Point-of-Care Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers

Oral, Head and Neck Oncology and Reconstructive Surgery – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Oral, Head and Neck Oncology and Reconstructive Surgery Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Oral, Head and Neck Oncology and Reconstructive Surgery is the first oral and maxillofacial surgery (OMS) text to provide you with a system for managing adult oral, head and neck cancers and reconstructive cranio-maxillofacial surgery. Using an evidence-based approach to the management and treatment of a wide variety of clinical conditions, the extensive experience of the author and contributors in head and neck/cranio-maxillofacial surgery and oncology are highlighted throughout the text. This includes computer aided surgical simulation, intraoperative navigation, robotic surgery, endoscopic surgery, microvascular surgery, molecular science, and tumor immunology. In addition, high quality photos and illustrations are accompanied by videos of surgical procedures that are easily accessible on mobile devices.

Read more and order at Oral, Head and Neck Oncology and Reconstructive Surgery

Biomarkers in Cancer Screening and Early Detection. Translational Oncology – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Biomarkers in Cancer Screening and Early Detection. Translational Oncology Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state–of–the–art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and clinical use. The primary purpose of this book is to summarize and present best practices in this field to date, and offer actionable information and hopefully also inspiration to move discovery and clinical application forward.

This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection is organized into three sections: Section I lays the foundation for biomarker discovery, development and validation. Section II presents organ–specific topics relevant to the clinical needs in early detection, the natural history of the disease and associated evidence in support of biomarker research, an overview of the current state–of–the art in biomarker research, current progress toward bringing these biomarkers into clinical use and the future of biomarker–based screening and early detection for the respective organ type. Finally, Section III offers chapters that address the current screening strategies for selected organ types, discuss deficiencies with the present practice and identify clinical needs that may benefit from biomarker–based approaches.

This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection:

  • Provides immediately actionable information and hopefully also inspiration to move discovery and clinical application forward
  • Considers the cutting edge "bench to bedside and back" breakthroughs which have transformed the diagnosis, prognosis and treatment of cancer
  • Discusses screening guidelines, research strategies, and issues surrounding cancer overdiagnosis
  • Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers

The development of cancer is preceded by numerous mutations and changes which transform normal cells into benign tumors, and progressively into malignant and metastatic forms. This enormous complexity makes cancer detection, diagnosis, and treatment challenging and therefore the ability to identify tumors that are destined to progress at an early stage will allow effective treatment interventions and reduce deaths. This new book comprehensively summarises the current state of play and is an ideal resource for clinical and research oncologists interested in the progress of screening and detection of cancer.

Read more and order at Biomarkers in Cancer Screening and Early Detection. Translational Oncology

Oncologists – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Oncologists Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Brief Excerpt from Industry Overview Chapter

Physicians in this industry engage in the medical practice of diagnosing and treating cancer. Major US companies include Dana-Farber Cancer Institute, Johns Hopkins, Mayo Clinic, MD Anderson Cancer Center, and Memorial Sloan-Kettering Cancer Center. Leading providers of cancer treatment outside the US include Institut Gustave-Roussy (based in France), the Princess Margaret Hospital (Canada), the Royal Marsden Hospital (the UK), and Sun Yat-Sen University Cancer Center (China).

Competitive Landscape

Demand for oncologists is driven by the number of people being treated for cancer. Profitability depends on patient volume, insurance reimbursement, reputation, and operational efficiency. Large organizations have economies of scale in purchasing and administration. Small clinics can compete by treating specific types of cancer or patient groups, such as children.

Products, Operations & Technology

Oncologists diagnose and treat tumors, perform surgery, track patients in remission, provide medical support to terminally ill patients, and research causes and treatments of cancer. In addition to revenue from diagnosis and disease management, a significant portion of industry revenue comes from the sale of pharmaceuticals. Revenue is also generated from laboratory and image testing fees.

Read more and order at Oncologists

The Human Body – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The The Human Body Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

The Human Body: Linking Structure and Function provides knowledge on the human body's unique structure and how it works. Each chapter is designed to be easily understood, making the reading interesting and approachable. Organized by organ system, this succinct publication presents the functional relevance of developmental studies and integrates anatomical function with structure.

  • Focuses on bodily functions and the human body's unique structure
  • Offers insight into disease and disorders and their likely anatomical origin
  • Explains how developmental lineage influences the integration of organ systems

Read more and order at The Human Body

Viral Oncology. Basic Science and Clinical Applications – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Viral Oncology. Basic Science and Clinical Applications Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

A comprehensive look at the latest research findings and clinical applications of oncogenic viruses

Written by a panel of academic experts, Viral Oncology is the first self–contained and comprehensive book to present both scientific and clinical information on viruses linked to some of the most important human cancers. Readers can turn to this book for the most in–depth and up–to–date coverage of: HPV–associated cancers; molecular events associated with HPV–induced human cancer; the role of the HPV E6 oncoprotein in malignant progression; virus association with brain tumors; involvement of the polyomavirus JCV in colorectal cancer; possibleassociation of BKV with prostate cancer; oncogenic transformation bypolyomavirus large T antigen; SV40 and human cancer; SV40 and mesothelioma; molecular immunology of hepatitis B associated viral cancer; hepatitis B vaccine and hepatocellular carcinoma; pathogenesis of acute and chronic hepatitis Cvirus infection; molecular mechanisms of hepatitis C virus–induced cellulartransformation; clinical aspects of HTLV–1 associated cancer; oncogenic potential of the HTLV–1 tax protein; HIV–associated malignancy; HIV–related lymphoma; biology and epidemiology of HHV–8; the role of KSHV in pathogenesis of Kaposi′ssarcoma; molecular pathobiology of EBV infection; and EBV as a pathogen.

Several chapters are devoted to the basic science of oncogenic viruses for thestudy of their pathogenesis, drug development, and employment of viral vectorsfor vaccine and gene therapy. The book also includes complementary clinically based chapters describing natural courses and treatments. Additionally, bonusclinical materials are embedded within chapters and an easy–to–use indexcompletes the book.

Viral Oncology is an essential resource for clinical and research oncologists in medical facilities and biological research laboratories; clinicians and scientists working in related biomedical areas; medical students working toward a first or higher degree in the life sciences and other biomedical fields; and pharmaceutical scientists and developers.

Read more and order at Viral Oncology. Basic Science and Clinical Applications

Pediatric Hematology and Oncology. Scientific Principles and Clinical Practice – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Pediatric Hematology and Oncology. Scientific Principles and Clinical Practice Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

This new textbook has an international authorship and is a practical, up–to–date resource for clinicians responsible for the care of children with oncologic and malignant hematologic disease. It is specifically designed for practicing oncologists and hematologists, pediatricians with an interest in childhood cancer and trainees seeking a systematic approach to these disorders.   This new textbook has an emphasis on the visual presentation and ease of reading of contemporary and comprehensive information for children s cancers and contains detailed tables, fact boxes and illustrations.

The textbook begins with an introduction to the general principles of the scientific foundation and treatment of childhood cancers and hematological malignancies. Separate sections are then devoted to descriptions of central nervous system tumors, hematological malignancies and solid tumors of childhood which encompass epidemiology, cellular and molecular biology, cancer genetics, immunology, pharmacology and the findings of clinical trials. For each area of science covered, key original references and reviews are highlighted to direct further reading.

Diagnostic, biological, and therapeutic issues are integrated into each tumor–specific chapter, with evidence supporting the current rationales for risk stratification and the development of novel therapies. A final section then explores supportive care, palliative care, late effects considerations and psychosocial issues as relate to children s cancer.

Read more and order at Pediatric Hematology and Oncology. Scientific Principles and Clinical Practice

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Immuno-oncology is a unique approach that uses the body’s immune system to fight cancer. These therapies activate an individual’s immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.

According to the report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022”, the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.

The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).

The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.

On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

Read more and order at Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)], By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022